• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LUO Yu,YIN Xiangnan,XU Qiang,WANG Tao.Inflammatory mechanisms of hyperuricemia and strategies for drug development[J].Journal Of Pharmaceutical Research,2025,44(11):1,119-11,271,144[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2018times   Download 764次 QR Code for this article
Scan with your phone!
高尿酸血症的炎症机制及药物研发策略
罗玉,尹向楠,徐强,王涛
Font:Larger+|Default|Smaller-
(中国药科大学多靶标天然药物全国重点实验室,江苏 南京 210009)
摘要:
高尿酸血症(HUA)是痛风、代谢综合征及心血管疾病的独立危险因素,全球成人患病率高达16%~20%。近年研究揭示,炎症在HUA病理进程中占据核心地位,通过激活NOD样受体热蛋白结构域相关蛋白3(NLRP3)炎症小体触发白介素-1β(IL-1β)释放,启动先天免疫应答;树突状细胞进一步介导辅助性T细胞17/调节性T细胞失衡,放大适应性免疫炎症级联。同时,部分炎症因子通过上调黄嘌呤氧化酶活性、抑制尿酸排泄形成“尿酸-炎症”恶性循环,加重器官损伤。传统降尿酸药物虽可控制血尿酸水平,但无法阻断炎症通路,而靶向NLRP3通路抑制剂、兼具抗炎/降尿酸双重功能药物(如改良非甾体抗炎药)及代谢调控策略为治疗HUA提供新方向。解析炎症-代谢交互网络,是开发HUA精准疗法的关键。
关键词:  高尿酸血症  炎症  先天免疫细胞  辅助性T细胞17/调节性T细胞  炎症因子
DOI:10.13506/j.cnki.jpr.2025.11.012
基金项目:
Publication Date:November 25, 2025
Inflammatory mechanisms of hyperuricemia and strategies for drug development
LUO Yu,YIN Xiangnan,XU Qiang,WANG Tao
(State Key Laboratory of Natural Medicines,China Pharmaceutical University,Nanjing 210009,China)
Abstract:
Hyperuricemia (HUA) is an independent risk factor for gout, metabolic syndrome, and cardiovascular diseases, with a global adult prevalence rate of 16%-20%. Recent studies have revealed that the inflammatory plays a central role in the pathological process of HUA. It triggers the release of IL-1β by activating the NLRP3 inflammasome, initiating the innate immune response; dendritic cells (DCs) further mediate the Th17/Treg imbalance, amplifying the adaptive immune inflammatory cascade. Meanwhile, inflammatory cytokines (such as IL-1β, TNF-α) up-regulate the activity of xanthine oxidase and inhibit uricosuria, forming a vicious cycle of "urate-inflammation", which exacerbates organ damage. Although traditional urate-lowering drugs can control serum uric acid levels, they cannot block the inflammatory pathway. Targeted NLRP3 pathway inhibitors, drugs with dual anti-inflammatory/uricosuric functions (such as modified NSAIDs), and metabolic regulation strategies provide new directions for treatment. Analyzing the inflammation-metabolism interaction network is key to developing precise therapies for HUA.
Key words:  Hyperuricemia  Inflammation  Innate immune cells  Th17/Treg and inflammatory cytokines
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.